Brennan Aoife 4

Accession 0000950170-23-063927

CIK 0001527599other

View on SEC.gov Company Profile

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 7:23 PM ET

Size

45.6 KB

Accession

0000950170-23-063927

Insider Transaction Report

Form 4

Period: 2023-11-10

SYNLOGIC, INC.SYBX

Brennan Aoife

Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2023-11-10−5,591→ 0 total
Exercise: $202.95Exp: 2027-05-15→ Common Stock (5,591 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−3,733→ 0 total
Exercise: $149.25Exp: 2028-03-14→ Common Stock (3,733 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−3,600→ 0 total
Exercise: $143.25Exp: 2028-06-05→ Common Stock (3,600 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−9,999→ 0 total
Exercise: $118.65Exp: 2028-10-31→ Common Stock (9,999 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−12,332→ 0 total
Exercise: $128.85Exp: 2029-03-05→ Common Stock (12,332 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−12,352→ 0 total
Exercise: $25.50Exp: 2030-03-10→ Common Stock (12,352 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−18,999→ 0 total
Exercise: $52.50Exp: 2031-03-10→ Common Stock (18,999 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−28,943→ 0 total
Exercise: $29.25Exp: 2032-02-04→ Common Stock (28,943 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−42,999→ 0 total
Exercise: $9.30Exp: 2033-03-16→ Common Stock (42,999 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-11-10−8,666→ 0 total
Exercise: $9.30Exp: 2033-03-16→ Common Stock (8,666 underlying)
Award
Stock Option (right to buy)
2023-11-10+5,591→ 5,591 total
Exercise: $1.85Exp: 2027-05-15→ Common Stock (5,591 underlying)
Award
Stock Option (right to buy)
2023-11-10+3,733→ 3,733 total
Exercise: $1.85Exp: 2028-03-14→ Common Stock (3,733 underlying)
Award
Stock Option (right to buy)
2023-11-10+3,600→ 3,600 total
Exercise: $1.85Exp: 2028-06-05→ Common Stock (3,600 underlying)
Award
Stock Option (right to buy)
2023-11-10+9,999→ 9,999 total
Exercise: $1.85Exp: 2028-10-31→ Common Stock (9,999 underlying)
Award
Stock Option (right to buy)
2023-11-10+12,332→ 12,332 total
Exercise: $1.85Exp: 2029-03-05→ Common Stock (12,332 underlying)
Award
Stock Option (right to buy)
2023-11-10+12,352→ 12,352 total
Exercise: $1.85Exp: 2030-03-10→ Common Stock (12,352 underlying)
Award
Stock Option (right to buy)
2023-11-10+18,999→ 18,999 total
Exercise: $1.85Exp: 2031-03-10→ Common Stock (18,999 underlying)
Award
Stock Option (right to buy)
2023-11-10+28,943→ 28,943 total
Exercise: $1.85Exp: 2032-02-04→ Common Stock (28,943 underlying)
Award
Stock Option (right to buy)
2023-11-10+42,999→ 42,999 total
Exercise: $1.85Exp: 2033-03-16→ Common Stock (42,999 underlying)
Award
Stock Option (right to buy)
2023-11-10+8,666→ 8,666 total
Exercise: $1.85Exp: 2033-03-16→ Common Stock (8,666 underlying)

Footnotes (7)

[F1]In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
[F2]The shares subject to this option are fully vested as of the date hereof.
[F3]The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
[F4]The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
[F5]The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
[F6]The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
[F7]These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

SYNLOGIC, INC.

CIK 0001527599

→

Entity typeother

Related Parties

filerCIK 0001714563

Filing Metadata

Form type: 4
Filed: Nov 13, 7:00 PM ET
Accepted: Nov 14, 7:23 PM ET
Size: 45.6 KB

View on SEC.gov